|
π
|
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
64 auth.
HarryG. M. Heijerman,
E. McKone,
D. Downey,
E. V. Braeckel,
S. Rowe,
E. Tullis,
M. Mall,
J. Welter,
B. Ramsey,
C. Mckee,
G. Marigowda,
S. Moskowitz,
D. Waltz,
P. Sosnay,
C. Simard,
...
N. Ahluwalia,
F. Xuan,
Yaohua Zhang,
J. Taylor-Cousar,
K. McCoy,
K. McCoy,
S. Donaldson,
Seth Walker,
J. Chmiel,
R. Rubenstein,
D. Froh,
I. Neuringer,
M. Jain,
K. Moffett,
J. Taylor-Cousar,
Bruce Barnett,
Gary Mueller,
P. Flume,
Floyd Livingston,
N. Mehdi,
C. Teneback,
J. Welter,
R. Jain,
D. Kissner,
Kapilkumar Patel,
Francisco J. Calimano,
J. Johannes,
C. Daines,
T. Keens,
H. Scher,
S. Chittivelu,
Sudhakar Reddivalam,
R. Klingsberg,
L. Johnson,
S. Verhulst,
P. Macedo,
D. Downey,
G. Connett,
E. Nash,
N. Withers,
Timothy Lee,
M. Bakker,
HarryG. M. Heijerman,
F. Vermeulen,
C. Knoop,
E. Wachter,
R. V. D. Meer,
P. Merkus,
C. Majoor
|
9 |
2019 |
9
π
|
|
π
|
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.
25 auth.
G. Berkers,
P. van Mourik,
A. Vonk,
E. Kruisselbrink,
J. Dekkers,
K. M. de Winter-de Groot,
H. Arets,
Rozemarijn E P Marck-van der Wilt,
Jasper S Dijkema,
Maaike M. Vanderschuren,
R. Houwen,
H. Heijerman,
E. A. van de Graaf,
S. Elias,
C. Majoor,
...
G. Koppelman,
J. Roukema,
M. Bakker,
H. Janssens,
R. van der Meer,
R. Vries,
H. Clevers,
H. D. de Jonge,
J. Beekman,
C. K. van der Ent
|
7 |
2019 |
7
π
|
|
π
|
Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients
7 auth.
R. Hoek,
Marthe S. Paats,
S. Pas,
M. Bakker,
H. Hoogsteden,
C. Boucher,
...
M. M. van der Eerden
|
6 |
2013 |
6
π
|
|
π
|
Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis.
7 auth.
Rina La Distia Nora,
M. V. van Velthoven,
N. H. ten Dam-van Loon,
T. Misotten,
M. Bakker,
M. V. van Hagen,
...
A. Rothova
|
5 |
2014 |
5
π
|
|
π
|
History of tuberculosis as an independent prognostic factor for lung cancer survival.
12 auth.
Marlies E. Heuvers,
J. Aerts,
J. Hegmans,
J. Veltman,
A. Uitterlinden,
R. Ruiter,
...
E. Rodenburg,
A. Hofman,
M. Bakker,
H. Hoogsteden,
B. Stricker,
R. V. van Klaveren
|
5 |
2012 |
5
π
|
|
π
|
False-negative interferon-Ξ³ release assay results in active tuberculosis: a TBNET study
26 auth.
Veerle L. de Visser,
G. Sotgiu,
C. Lange,
M. Aabye,
M. Bakker,
F. Bartalesi,
K. Brat,
C. Chee,
K. Dheda,
J. DomΓnguez,
F. Eyuboglu,
Maha K. Ghanem,
D. Goletti,
A. DilektaΕlΔ±,
L. Guglielmetti,
...
W. Koh,
I. Latorre,
M. Losi,
M. Polanova,
P. Ravn,
F. Ringshausen,
R. Rumetshofer,
M. D. de Souza-GalvΓ£o,
S. Thijsen,
G. Bothamley,
A. Bossink
|
5 |
2014 |
5
π
|
|
π
|
Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course
14 auth.
J. Miedema,
M. Schreurs,
S. van der Sar β van der Brugge,
M. Paats,
Sara J. Baart,
M. Bakker,
R. Hoek,
W. Dik,
H. Endeman,
Vincent Van Der Velden,
...
A. V. van Gammeren,
A. Ermens,
J. Aerts,
J. ThΓΌsen
|
4 |
2021 |
4
π
|
|
π
|
Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis.
8 auth.
Marthe S. Paats,
I. Bergen,
M. Bakker,
R. Hoek,
Karin J. Nietzman-Lammering,
H. Hoogsteden,
...
R. Hendriks,
M. M. van der Eerden
|
4 |
2013 |
4
π
|
|
π
|
Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands
9 auth.
G. de Vries,
R. van Hest,
M. Bakker,
C. Erkens,
S. van den Hof,
W. Meijer,
...
K. Oud,
E. Slump,
J. V. van Dissel
|
4 |
2017 |
4
π
|
|
π¬
|
Prevalence Of Positive Quantiferon-Tb Gold In-Tube Test In Uveitis And Its Clinical Implications In A Country Non-Endemic For Tuberculosis.
F. Groen-Hakan,
J. V. van Laar,
M. Bakker,
P. M. van Hagen,
Hannah Hardjosantoso,
A. Rothova
|
3 |
2019 |
3
π¬
|
